Form 4: Incyte EVP & General Counsel Sheila Denton Reports Stock Transactions and New Equity Awards

Incyte Corporation's EVP & General Counsel, Sheila A. Denton, reported multiple transactions including stock option exercises, sales of common stock, and significant new equity awards on July 15 and 16, 2025.

Summary

• Sheila A. Denton, EVP & General Counsel of Incyte Corp (INCY), engaged in several stock transactions on July 15 and 16, 2025.
• On July 15, 2025, Denton exercised employee stock options to acquire 3,330 shares of common stock at a price of $64.25 per share.
• Concurrently, Denton sold 3,330 shares of common stock at $69.86 per share on July 15, 2025, and an additional 785 shares at $68.36 per share on July 16, 2025.
• 703 shares were automatically withheld by Incyte to satisfy tax withholding obligations due at settlement of previously reported restricted stock units, at a price of $68.25 per share.
• Denton received an award of 8,184 restricted stock units (RSUs) at $0, which will vest 25% annually over four years.
• A grant of 20,461 performance shares was also awarded at $0, which may yield up to 200% of one common share based on Incyte's relative total shareholder return (TSR) over a three-year performance period beginning January 1, 2025, and will vest on July 15, 2028.
• Additionally, 18,419 new employee stock options were granted with an exercise price of $68.25, vesting in 37 installments over three years after an initial one-year cliff.
• Following these transactions, Denton beneficially owns 33,200 shares of common stock, 9,993 employee stock options, and 20,461 performance shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are sales of common stock, these are offset by significant new equity awards (RSUs, performance shares, and new options), indicating continued long-term commitment and incentive for the executive. The sales appear to be related to option exercises and tax obligations, which are routine for executive compensation.

Positives

• Grant of 8,184 Restricted Stock Units (RSUs) at $0, vesting over four years, indicating continued long-term incentive for the executive.
• Award of 20,461 Performance Shares at $0, tied to the company's relative Total Shareholder Return (TSR) over three years, aligning executive incentives with shareholder value creation.
• Grant of 18,419 new Employee Stock Options at $0, providing future potential upside for the executive.

Negatives

• Sale of 3,330 shares of common stock at $69.86 and 785 shares at $68.36, representing a reduction in direct common stock holdings.
• 703 shares were withheld for tax obligations, reducing the net shares received from vested awards.

Future Outlook

The vesting schedules for the newly granted Restricted Stock Units (RSUs) and Performance Shares indicate a long-term incentive structure for the executive, aligning their interests with the company's future performance and shareholder return over the next three to four years.

Industry Context

This Form 4 reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where equity awards like RSUs and performance shares are commonly used to incentivize long-term performance and align executive interests with shareholder value. The exercise of options and subsequent sale of shares is a typical liquidity event for executives.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Shares as part of executive compensation is a common practice across the biotechnology and pharmaceutical sectors, similar to companies like Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD), which utilize similar long-term incentive vehicles to retain talent and align executive performance with company goals.
• The vesting schedule of 25% annually over four years for RSUs is a standard approach, comparable to equity grants at many large-cap biopharma companies.
• Performance shares tied to relative Total Shareholder Return (TSR) against a peer group is a robust performance metric, often seen in compensation plans at companies like Pfizer Inc. (PFE) or Merck & Co., Inc. (MRK), designed to reward outperformance against competitors.

Related Party Transactions

• The transactions detailed are related party transactions as they involve an executive officer of Incyte Corp and the company's equity securities.

Stakeholder Impact

• Shareholders: The executive's sales could be perceived as a slight negative, but the significant new equity grants (RSUs and performance shares) align the executive's long-term interests with shareholder value creation, potentially benefiting shareholders through incentivized performance.

Next Steps

• Continued vesting of 8,184 Restricted Stock Units (RSUs) annually over the next four years.
• Assessment of Incyte's relative Total Shareholder Return (TSR) over the three-year performance period beginning January 1, 2025, to determine the final number of earned performance shares.
• Vesting of 20,461 performance shares on July 15, 2028, subject to performance and continued service.
• Continued vesting of 18,419 new employee stock options over 37 installments, with the first 25% vesting after one year.

Key Dates

Recommendation

Keywords

Incyte Corp, INCY, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Shares, Executive Compensation, Sheila Denton, Stock Sale, Equity Awards